All posts by: Michael Zand

About Michael Zand

Gene Therapy Using ‘Junk DNA’ Could Lower Risk for Heart Disease – Newswise (press release)

Continue reading

2017-08-26 NEWS

Gene Therapy Using ‘Junk DNA’ Could Lower Risk for Heart Disease
Newswise (press release)
Although previous research has shown that lncRNAs can be important, this is the first study to show that they could potentially be used to treat a human disease using gene therapy. Junk genes could one day offer a framework for treating people with

and more »

Continue reading

2017-08-26 NEWS

Cancer Research UK (blog)

News digest – vitamin supplements, cancer ‘avatars’, immunotherapy targets, and… Wi-Fi worries?
Cancer Research UK (blog)
Men who take high doses of some vitamin B supplements might be at higher risk of lung cancer, particularly if they smoke, according to a US study. Taking daily supplements that far exceed the recommended intake for 10 years increased the risk of lung …

Continue reading

2017-08-26 NEWS

New ‘Dimension’ expands the gene therapy pipeline for Regenxbio
BioWorld Online
The deal, which values Dimension at less than $100 million, adds gene therapy candidates DTX-301 for ornithine transcarbamylase (OTC) deficiency and DTX-401 for glycogen storage disease type Ia (GSDIa) to Regenxbio’s metabolic disease franchise, …

Continue reading

2017-08-25 NEWS

Southernminn.com

Mayo Clinic, University of Minnesota develop ‘robocop’ stem cells to fight cancer
Southernminn.com
The so-called CAR T cellular therapies are expected to receive federal approval this fall for certain rare blood cancers — B-cell forms of lymphoma and leukemia. But scientists at the Minnesota institutions hope that’s just the first step that will
Blood Cancer 101 comes to Oak BayVictoria News

all 2 news articles »

Continue reading

2017-08-25 NEWS

Community Idea Stations

Life By Design: A Century of Synthetic Biology
Community Idea Stations
Newspapers today are full of accounts of the future marvels of “synthetic biology,” a new approach to engineering life. But, how new is it? Dr. Luis Campos takes us through the surprising history in an informal 20-minute talk followed by a Q & A given

and more »

Continue reading

2017-08-25 NEWS

Case Study Identifies New Trigger for CART Cell Expansion in DLBCL in JCAR017 Trial
AJMC.com Managed Markets Network
Chimeric antigen receptor (CAR)-T cells can re-expand in a patient months after the initial infusion and can also be active against the patient’s cancer. These are the findings of a single case study that was recently published in the New England